Defibrotide for Patients With Hepatic VOD: A Treatment IND Study
Status: Recruiting
Phase: Phase 3
Diagnosis: Veno-Occlusive Disease
NCT ID: NCT00628498
(View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 07-320
Single arm, open-label study to provide Defibrotide to patients diagnosed with VOD. Defibrotide is no longer available though the Emergency Use IND mechanism (also known as compassionate use, or single patient named use). This protocol is the only mechanism by which Defibrotide can be made available to patients in the U.S.
Conducting Institutions:
Dana-Farber Cancer Institute, Massachusetts General Hospital, Beth-Israel Deaconess Medical Center, Brigham and Women's Hospital, Children's Hospital Boston
Overall PI:
Paul Richardson, MD,
Dana-Farber Cancer Institute
Site-responsible Investigators:
David Avigan, MD,
Beth Israel Deaconess Medical Center
Leslie Lehmann, MD,
Dana-Farber Cancer Institute
Thomas Spitzer, MD,
Massachusetts General Hospital
Contacts:
Dana-Farber Cancer Institute:
Carolyn Revta, 617-632-2365,
carolyn_revta@dfci.harvard.edu
Massachusetts General Hospital:
Cancer Trials Call Center, 877-789-6100
Beth-Israel Deaconess Medical Center:
Cancer Trials Call Center, 617-667-3060
Eligibility Criteria
Inclusion Criteria:
Entry criteria include both of the following:
1.1 Clinical diagnosis of VOD, defined by jaundice (bilirubin ≥2 mg/dL) and at least 2 of
the following clinical findings, by Day +35 post stem cell transplant:
- Ascites
- Weight gain of >/= 5% compared to the day of conditioning-- if this value is not
available, the weight on the date of admission to the SCT unit may be used)
- Hepatomegaly; increased over baseline (at the time of admission for SCT).
Patients that do not meet the criteria in Section 1.1 (i.e. have two of the major criteria
but not three) and have biopsy proven VOD are eligible in the presence of characteristics
consistent with severe disease (see below)
1.2 Severe VOD, defined as VOD with multi-organ failure (MOF), i.e., presence of one or
both of the following, by Day +45 post stem cell transplant:
- Renal dysfunction:
- Serum creatinine > 3x value on the date of admission to the SCT unit for
conditioning or > 3x lowest value during conditioning prior to SCT (whichever is
lowest) or
- Creatinine clearance or GFR </= 40% of admission value, or
- Dialysis dependence; OR
- Pulmonary dysfunction:
- Documentation of oxygen saturation </= 90% on room air (two consecutive
measurements at least one hour apart) or
- Requirement for oxygen supplementation /ventilator dependence. Dysfunction must
be attributable to fluid overload or mechanical impingement from abdominal
distention or hepatic enlargement and not to an infectious cause (e.g.,
documented pneumonia).
- Patient must also provide written informed consent.
Exclusion Criteria:
- Use of any medication which increases the risk of hemorrhage is disallowed. Use of
heparin or other anticoagulants is disallowed within 12 hours unless being used for
routine central venous line management, fibrinolytic instillation for central venous
line occlusion, intermittent dialysis or ultrafiltration of CVVH.
- Clinically significant uncontrolled acute bleeding, defined as hemorrhage requiring >
15 cc/kg of packed red blood cells (e.g., a pediatric patient weighing 20 kg and
requiring > 300cc of packed red blood cells/24 hours, or an adult patient weighing 70
kg and requiring >3 units of packed red blood cells/24 hours) to replace blood loss,
OR bleeding from a site which in the Investigator's opinion constitutes a potential
life-threatening source (e.g. pulmonary hemorrhage or CNS bleeding), irrespective of
amount of blood loss, at any point from the date of SCT through the date of severe VOD
diagnosis.
- Hemodynamic instability as defined by a requirement for multiple pressors, or
inability to maintain mean arterial pressure (for children: to maintain mean arterial
pressure within 1 standard deviation of age-adjusted levels) with single pressor
support.
- NB: for sites that have been activated in Protocol Defibrotide 2005-01, patients
eligible for this Treatment IND protocol must meet a diagnosis of VOD After Day + 21
from SCT before Day + 3. In addition patients must meet diagnosis of MOF AFTER Day +
28 and BEFORE Day + 4. Patients who meet these criteria Before Day + 21 and Day +28,
respectively, must be enrolled in Protocol 2005-01.